+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Comparison between resveratrol and cabergoline in preventing ovarian hyperstimulation syndrome in a rat model



Comparison between resveratrol and cabergoline in preventing ovarian hyperstimulation syndrome in a rat model



Gynecological Endocrinology 32(8): 634-640



The aim of this study is to investigate the effects of resveratrol in a rat model of ovarian hyperstimulation syndrome (OHSS) and compare with cabergoline. Randomized controlled, animal study. Female Wistar rats. A rat OHSS model was used to investigate the effects of resveratrol compare with cabergoline administration for preventing OHSS. Body weight, ovary weight, diameter, vascular permeability (VP), vascular endothelial growth factor (VEGF), cyclooxygenase-2 (COX-2) expression (immunohistochemistry), and serum estradiol (E2) levels were then compared. The ovarian VEGF concentration was significantly increased in the OHSS Groups (Groups 3-5) compared with the control groups (1 and 2). But vascular permeability, VEGF, and COX-2 expressions were reduced in animals treated with the resveratrol group compared with the cabergoline group (group 5) and the severe OHSS (group 3) group. Blood E2 levels were decreased in group treated with the resveratrol group compared with the cabergoline group (group 5) and severe the OHSS (group 3) group. Our results in a rat model suggest that resveratrol has a beneficial effect on OHSS by reducing the increases in ovarian daimeter, VP, and VEGF expression associated with OHSS. These effects may be mediated by the COX-2 inhibitory capacity of resveratrol.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 057462299

Download citation: RISBibTeXText

PMID: 26939766

DOI: 10.3109/09513590.2016.1152575


Related references

PP-024 - Comparison between resveratrol and cabergoline in preventing ovarian hyperstimulation syndrome in a rat model. Reproductive Biomedicine Online 32: S11-S13, 2016

Comparison of bevacizumab and cabergoline in the treatment of ovarian hyperstimulation syndrome in a rat model. Gynecological Endocrinology 29(9): 851-854, 2013

Cabergoline for preventing ovarian hyperstimulation syndrome. Cochrane Database of Systematic Reviews 2012(2): Cd008605, 2012

Prevention of ovarian hyperstimulation syndrome in a rat model: efficacy comparison between cabergoline and meloxicam. Acta Obstetricia et Gynecologica Scandinavica 89(5): 692-699, 2010

Comparison of montelukast and cabergoline for prevention of ovarian hyperstimulation syndrome: in an experimental rat model. Gynecological Endocrinology 31(5): 369-373, 2015

Preventing ovarian hyperstimulation syndrome: cabergoline versus coasting. Archives of Gynecology and Obstetrics 288(5): 1159-1163, 2013

Comparison of the effects of letrozole and cabergoline on vascular permeability, ovarian diameter, ovarian tissue VEGF levels, and blood PEDF levels, in a rat model of ovarian hyperstimulation syndrome. Archives of Gynecology and Obstetrics 293(5): 1101-1106, 2016

Prevention of ovarian hyperstimulation syndrome in a rat model: comparison of the efficacy of tocilizumab with that of ranibizumab, cabergoline, and a gonadotropin-releasing hormone antagonist. Gynecological Endocrinology 31(12): 949-954, 2015

Randomized trial of combined cabergoline and coasting in preventing ovarian hyperstimulation syndrome during in vitro fertilization/intracytoplasmic sperm injection cycles. International Journal of Gynaecology and Obstetrics: the Official Organ of the International Federation of Gynaecology and Obstetrics 140(2): 217-222, 2018

Comparison of albumin and cabergoline in the prevention of ovarian hyperstimulation syndrome: A clinical trial study. Iranian Journal of Reproductive Medicine 11(10): 837-842, 2013

Cabergoline for preventing ovarian hyperstimulation syndrome in women at risk undergoing in vitro fertilization/intracytoplasmic sperm injection treatment cycles: A randomized controlled study. Avicenna Journal of Medicine 5(4): 123-127, 2015

GnRH antagonist rescue protocol combined with cabergoline versus cabergoline alone in the prevention of ovarian hyperstimulation syndrome: a randomized controlled trial. Journal of Ovarian Research 9(1): 29, 2016

Comparison of cabergoline and intravenous albumin in the prevention of ovarian hyperstimulation syndrome: a randomized clinical trial. Journal of Assisted Reproduction and Genetics 29(3): 259-264, 2012

The effects of resveratrol on ovarian hyperstimulation syndrome in a rat model. Taiwanese Journal of Obstetrics and Gynecology 57(3): 383-388, 2018

Comparison of Cabergoline and Quinagolide in Prevention of Severe Ovarian Hyperstimulation Syndrome among Patients Undergoing Intracytoplasmic Sperm Injection. International Journal of Fertility and Sterility 12(1): 1-5, 2018